| Study number [ref.] | Sensitivity % | Specificity % | PPV % | NPV % | PLR | NLR |
| 84 [6] | 96.8 (93.8–98.6) | 4.6 (2.6–7.6) | 44.1 (39.3–48.4) | 65.2 (42.7–83.6) | 1.02 (0.98–1.05) | 0.68 (0.30–1.59) |
| 100033 [7] | 91.8 (88.9–94.0) | 19.2 (15.6–23.3) | 56.6 (53.1–60.1) | 66.9 (57.8–75.2) | 1.14 (1.08–1.20) | 0.43 (0.30–0.61) |
| 100034# | 95.3 (92.0–97.5) | 24.4 (20.2–29.0) | 47.0 (42.8–51.3) | 88.0 (80.3–93.4) | 1.26 (1.18–1.34) | 0.19, (0.11–0.34) |
| 100160 [8] | 96.8 (93.9–98.5) | 16.5 (12.3–21.5) | 54.1 (49.6–58.6) | 83.3 (97.7–92.10 | 1.16 (1.09–1.23) | 0.20 (0.10–0.39) |
| 100243 [9] | 95.6 (92.7–97.6) | 13.6 (9.7–18.2) | 56.1 (51.7–60.3) | 72.6 (58.3–84.1) | 1.11 (1.05–1.17) | 0.33 (0.18–0.59) |
| 240017 [10] | 91.1 (87.2–94.2) | 18.9 (15.4–22.9) | 41.6 (37.6–45.6) | 77.1 (68.0–84.6) | 1.12 (1.06–1.19) | 0.47 (0.31–0.72) |
| Pooled | 94.8 (92.1–97.4) | 15.0 (6.7–23.3) | NC | NC | NC | NC |
PPV: positive predictive value; NPV: negative predictive value; PLR: positive likelihood ratio; NLR: negative likelihood ratio; NC: not calculated. #: data held on file by Bayer Schering Pharma.